Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 22
1958 21
1959 21
1960 17
1961 14
1962 11
1965 6
1966 10
1967 12
1968 16
1969 16
1970 19
1971 22
1972 10
1973 8
1974 7
1975 24
1976 13
1977 5
1978 3
1979 15
1980 3
1981 2
1983 4
1984 4
1985 3
1986 2
1987 1
1988 7
1989 5
1990 5
1991 6
1992 5
1993 6
1994 7
1995 17
1996 45
1997 54
1998 66
1999 69
2000 85
2001 78
2002 91
2003 104
2004 100
2005 84
2006 111
2007 210
2008 183
2009 204
2010 251
2011 205
2012 232
2013 263
2014 308
2015 331
2016 329
2017 305
2018 328
2019 260
2020 16
Text availability
Article attribute
Article type
Publication date

Search Results

4,265 results
Results by year
Filters applied: . Clear all
Page 1
Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor.
Fralick M, Schneeweiss S, Patorno E. Fralick M, et al. N Engl J Med. 2017 Jun 8;376(23):2300-2302. doi: 10.1056/NEJMc1701990. N Engl J Med. 2017. PMID: 28591538 No abstract available.
[Adverse effects of oral hypoglycemic agents].
Mori Y, Sekihara H. Mori Y, et al. Nihon Rinsho. 2002 Sep;60 Suppl 9:325-31. Nihon Rinsho. 2002. PMID: 12387013 Review. Japanese. No abstract available.
Risks Associated with SGLT2 Inhibitors: An Overview.
Singh M, Kumar A. Singh M, et al. Curr Drug Saf. 2018;13(2):84-91. doi: 10.2174/1574886313666180226103408. Curr Drug Saf. 2018. PMID: 29485006 Review.
Adverse Effects of Glycemia-Lowering Medications in Type 2 Diabetes.
Razavi-Nematollahi L, Ismail-Beigi F. Razavi-Nematollahi L, et al. Curr Diab Rep. 2019 Nov 20;19(11):132. doi: 10.1007/s11892-019-1266-7. Curr Diab Rep. 2019. PMID: 31748838 Review.
Cardiovascular outcome trials of glucose-lowering medications: an update.
Home P. Home P. Diabetologia. 2019 Mar;62(3):357-369. doi: 10.1007/s00125-018-4801-1. Epub 2019 Jan 3. Diabetologia. 2019. PMID: 30607467 Review.
SGLT2 inhibitors: are they safe?
Filippas-Ntekouan S, Filippatos TD, Elisaf MS. Filippas-Ntekouan S, et al. Postgrad Med. 2018 Jan;130(1):72-82. doi: 10.1080/00325481.2018.1394152. Epub 2017 Oct 27. Postgrad Med. 2018. PMID: 29039237 Review.
DPP-4 inhibitors: focus on safety.
Tella SH, Rendell MS. Tella SH, et al. Expert Opin Drug Saf. 2015 Jan;14(1):127-40. doi: 10.1517/14740338.2015.977863. Epub 2014 Dec 9. Expert Opin Drug Saf. 2015. PMID: 25488788 Review.
Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials.
Jabbour S, Seufert J, Scheen A, Bailey CJ, Karup C, Langkilde AM. Jabbour S, et al. Diabetes Obes Metab. 2018 Mar;20(3):620-628. doi: 10.1111/dom.13124. Epub 2017 Oct 26. Diabetes Obes Metab. 2018. PMID: 28950419 Free PMC article. Review.
4,265 results
Jump to page
Feedback